Zacks Research Downgrades LifeStance Health Group (NASDAQ:LFST) to Hold

LifeStance Health Group (NASDAQ:LFST) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

Other equities research analysts have also issued reports about the company. BTIG Research initiated coverage on LifeStance Health Group in a research report on Friday, July 25th. They set a “buy” rating and a $8.00 target price on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of LifeStance Health Group in a report on Wednesday, October 8th. UBS Group upped their price objective on shares of LifeStance Health Group from $8.50 to $9.00 and gave the company a “buy” rating in a research note on Friday, August 8th. Finally, Wall Street Zen downgraded shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $8.83.

LifeStance Health Group Price Performance

Shares of LFST traded up $0.04 during mid-day trading on Wednesday, hitting $6.29. The company’s stock had a trading volume of 4,297,370 shares, compared to its average volume of 1,993,876. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.48 and a quick ratio of 1.48. The firm has a 50-day moving average price of $5.29 and a 200 day moving average price of $5.27. LifeStance Health Group has a fifty-two week low of $3.74 and a fifty-two week high of $8.30. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -125.80 and a beta of 1.15.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Thursday, November 6th. The company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. The firm had revenue of $363.81 million during the quarter, compared to analysts’ expectations of $355.06 million. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. The firm’s revenue for the quarter was up 16.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.02) earnings per share. LifeStance Health Group has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

Insiders Place Their Bets

In other LifeStance Health Group news, major shareholder Summit Partners L. P sold 8,407,643 shares of LifeStance Health Group stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the transaction, the insider owned 33,524,715 shares of the company’s stock, valued at $169,970,305.05. The trade was a 20.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Darren M. Black sold 8,407,643 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.07, for a total value of $42,626,750.01. Following the completion of the transaction, the director owned 33,524,715 shares in the company, valued at $169,970,305.05. This represents a 20.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 20,407,643 shares of company stock worth $103,466,750. 3.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LFST. Teacher Retirement System of Texas purchased a new position in shares of LifeStance Health Group during the 1st quarter valued at $130,000. DekaBank Deutsche Girozentrale acquired a new stake in LifeStance Health Group during the first quarter valued at $31,000. Cornerstone Investment Partners LLC acquired a new stake in LifeStance Health Group during the first quarter valued at $156,000. Xponance Inc. purchased a new position in LifeStance Health Group in the first quarter valued at about $69,000. Finally, MQS Management LLC acquired a new position in LifeStance Health Group in the 1st quarter worth about $119,000. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.